Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic CD19/CD20-specific CAR-T cells P-CD19CD20-ALLO1

An off-the-shelf (OTS) preparation of human allogeneic T lymphocytes containing primarily stem cell memory T cells (Tscm) that have been genetically modified to express two chimeric antigen receptors (CARs) targeting the tumor-associated antigens (TAAs) CD19 and CD20, with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic CD19/CD20-specific CAR-T cells P-CD19CD20-ALLO1 specifically recognize and induce selective toxicity in CD19- and/or CD20-expressing tumor cells. Both CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies. Targeting both CD19 and CD20 may prevent tumor cell antigen escape and relapse.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic anti-CD19/anti-CD20 CAR T cells P-CD19CD20-ALLO1
allogeneic T stem cell memory CAR-T cells P-CD19CD20-ALLO1
allogeneic Tscm CAR-T cells P-CD19CD20-ALLO1
Code name:P-CD19CD20-ALLO 1
P-CD19CD20-ALLO-1
P-CD19CD20-ALLO1
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search